Sor102 [cracked]

The Future of IBD Care: Unpacking the SOR102 Oral Bispecific Antibody

Please provide more details so I can assist you accurately.

Greater decreases in the and rectal bleeding. sor102

SOR102: A Breakthrough in Oral Biologics for Ulcerative Colitis

For decades, the gold standard for treating has relied on systemic biologics—effective, yet often tethered to the "needle" and a host of systemic side effects. However, a new player, SOR102 , is making waves by rethinking how we deliver medicine directly to where it's needed: the gut. The Future of IBD Care: Unpacking the SOR102

If "sor102" is a course or educational topic, here's a basic outline:

Patients receiving SOR102 twice daily (BID) showed notable improvements over 6 weeks: However, a new player, SOR102 , is making

One patient reported a mild TEAE of catheter site pain and another patient reported a mild TEAE of headache in the placebo group. ... ScienceDirect.com Study Details | NCT06080048 - Clinical Trials SOR102-101 is a Phase 1, 3-part, randomised, double-blind, placebo-controlled, FIH study to determine the safety, tolerability, an... Clinical Trials.gov Reaching the therapeutic ceiling in IBD: Can Advanced Combination ... SOR102 was well tolerated across all doses, with no systemic exposure of the drug or its monomers, supporting its gut-targeted act... ScienceDirect.com Publications - Sorriso Pharmaceuticals The Lancet Gastroenterology & Hepatology. | 2025. Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and i... Sorriso Pharmaceuticals Safety and pharmacokinetics of SOR102, an oral bispecific ... Dec 22, 2025 —

By working directly in the GI tissue, it may achieve higher local concentrations than systemic drugs without increasing the risk of body-wide infections.

Localized activity confirmed by minimal systemic drug levels in the blood. Why it Matters: Breaking the "Therapeutic Ceiling"